Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Pfizer Seeks Piece of J&J’s Largest Pie With Remicade Biosimilar

By Andrew Berg | October 18, 2016

Pfizer will begin selling a cheaper version of one of Johnson & Johnson’s (J&J) most popular products. 

Pfizer announced Monday that it will begin shipment of Inflectra, a biosimilar of J&J’s rheumatoid-arthritis treatment Remicade, to wholesalers in the United States in late November 2016.

The company says Inflectra will be the first biosimilar monoclonal antibody (mAb) and only the second biosimilar to be available in the United States.

Inflectra is approved for the treatment of adult patients and pediatric patients with Chrons disease, ulcerative colitis, as well rheumatoid arthritis.

J&J has already contested Inflectra, but a federal court on Wednesday ruled that the drug does not infringe on J&J’s patent. J&J said it will appeal the ruling.

According to a report on the Wall Street Journal’s website, Remicade, which was first approved for sale in the United States in 1998, is J&J’s largest product by sales. The drug accounted for $6.5 billion in sales last year.

Pfizer said that Inflectra will be introduced at a 15 percent discount to the current wholesaler acquisition cost (WAC) of Remicade.

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE